Boger Laboratory Publications

Educational Abstracts:

1.  Keith K, Anderson K, Wilson KD, Hazen-Martin D, Kern D, Boger HA.  An Innovative Approach to Geriatric Medicine Preparedness:  The MUSC Senior Mentor Program.  2016 AAMC Learn Serve Lead Conference.  Seattle, Washington, November, 2016 (Poster).

Peer-Reviewed Research Journal Articles:  

1. Quintero EM, Willis LM, Zaman V, Lee J, Boger HA, Tomac A, Hoffer BJ, Strömberg I, Granholm A-Ch.  2004.  GDNF is essential to neuronal survival in the locus coeruleus-hippocampal noradrenergic pathway.  Neuroscience. 124:137-146. Impact Factor 3.292.

2. Griffin III WC, Boger HA, Granholm A-Ch, Middaugh LD.  2006.  Partial Deletion of Glial Cell Line-Derived Neurotrophic Factor (GDNF) in Mice:  Effects on Sucrose Reward and Striatal GDNF Concentrations.  Brain Research 1068(1):257-60. Impact Factor 2.463.

3. Boger HA, Middaugh LD, Huang P, Smith AC, Zaman V, Hoffer BJ, Tomac AC, Granholm A-Ch.  2006.  A partial GDNF depletion exacerbates age-related motor dysfunction and degeneration of nigral dopamine neurons.  Experimental Neurology 202(2):336-47. Impact Factor 3.914.

4. af Bjerkén S, Boger HA, Nelson M, Hoffer BJ, Granholm A-Ch, Stromberg I. 2007.  Effects of glial cell line-derived neurotrophic factor deletion on ventral mesencephalic organotypic tissue cultures. Brain Research 1133(1):10-9. Impact Factor 2.463.

5. Boger HA, Middaugh LD, Patrick KS, Ramamoorthy S, Denehy ED, Zhu H, Pacchioni AM, Granholm A-Ch, McGinty JF. 2007. Long-term consequences of methamphetamine exposure in young adults are exacerbated in GDNF heterozygous mice.  Journal of Neuroscience 27(33):8816-8825. Impact Factor 8.238.

6. Boger HA, Middaugh LD, Zaman V, Hoffer BJ, Granholm A-Ch. 2008. Differential effects of the dopamine neurotoxin MPTP upon animals with a partial deletion of the GDNF receptor, GFRa1, gene.  Brain Research 1241: 18-28.   Impact Factor 2.463.

7. Zaman V, Boger HA, Granholm A-Ch, Rohrer B, Moore AB, Gerhardt GA, Hoffer AJ, Middaugh LD.  2008. Nigrostriatal Dopamine System of Aging GFRa-1 Heterozygous Mice: Neurochemistry, Morphology and Behavior.  European Journal of Neuroscience 28:1557-1568.  Impact Factor 3.418.

8.Granholm A-Ch, Boger HA, Emborg M.  2008.  Mood, memory and movement:  an age-related neurodegenerative complex?  (A Review) Current Aging Science 1: 133-139.  Impact Factor 5.01.

9. Boger HA, Middaugh LD, Granholm A-Ch, McGinty JF.  2009. Minocycline Restores Striatal Tyrosine Hydroxylase in GDNF Heterozygous Mice but not in Methamphetamine-treated Mice.  Neurobiology of Disease 33: 459-466.  Impact Factor 4.518.

10. Boger HA, Granholm A-Ch, McGinty JF, Middaugh LD.  2010.  A dual-hit hypothesis for age-related parkinsonism.  Progress in Neurobiology Special Issue "The Progressive Field of Monoamine Research" in honor of Nils-Ake Hillarp and His Students. Progress in Neurobiology 90(2):217-29. Impact Factor 9.140.

11. Boger HA, Samuvel DJ, Saylor AJ, Bender TS, McGinty JF, Zaman V, Huang P, Middaugh LD, Jayanthi LD, Rohrer B, Helke KL, Granholm A-Ch, Ramamoorthy S. 2011. Effects of brain-derived neurotrophic factor on dopaminergic function and motor behavior during aging. Genes, Brain, and Behavior 10:186-98. Impact Factor 3.795.

12. Granholm A-Ch, Zaman V, Godbee J, Smith M, Ramadan R, Umphlet CD, Randall P, Bhat NR, Rohrer B, Middaugh LD, Boger HA.  2011.  Prenatal LPS increases inflammation in the substantia nigra of Gdnf heterozygous mice.  Brain Pathology 21:330-48. Impact Factor 5.903.

13. Lockrow JP, Boger HA, Bimonte-Nelson HA, Granholm A-Ch. 2011. Effects of long-term memantine on memory and neuropathology in Ts65Dn mice, a model for Down syndrome.  Behavioural Brain Research 221:610-22. Impact Factor 3.220.

14. Lockrow JP, Boger HA, Gerhardt GA, Granholm A-Ch.  2011.  A noradrenergic lesion exacerbates neurodegeneration in a Down syndrome mouse model. Journal of Alzheimer’s Disease 23:471-89. Impact Factor 5.101.

15. Littrell OM, Pomerleau F, Huettl P, Surgener S., Middaugh LD, Granholm A-Ch, Gerhardt GA, Boger HA.  2012.  Enhanced Dopamine Transporter Activity in Middle-Aged Gdnf+/- Mice.  Neurobiology of Aging 33:427.e1-14. Impact Factor 5.937.

16. Littrell OM, Granholm A-Ch, Gerhardt GA, Boger HA.  2013. Glial cell-line derived neurotrophic factor (GDNF) replacement attenuates motor impairments and nigrostriatal dopamine deficits in 12-month-old mice with a partial deletion of GDNF.  Pharmacology, Biochemistry and Behavior 104:10-9. Impact Factor 2.532.2. 

17. Reinert KR, Umphlet CD, Quattlebaum A, Boger HA.  2014.  Short-term effects of an endotoxin on Substantia Nigra Dopamine Neurons.  Brain Research 1557:164-70. Impact Factor: 2.828.

18. Karakostas T, Hsiang S, Boger HA, Middaugh L, Granholm AC.  2014.  Three-dimensional rodent motion analysis and neurodegenerative disorders.  J Neurosci Methods. 231:31-7. Impact Factor: 1.959 532

20. Shen HW, Scofield MD, Boger HA, Hensley M, Kalivas PW. 2014. Synaptic glutamate spillover due to impaired glutamate uptake mediates heroin relapse.  J Neurosci. 34:5649-57. Impact Factor: 6.747.

21. Nie X, Hamlett ED, Granholm A, Hui ES, Helpern JA, Jensen JH, Boger HA, Collins HR, Falangola MF.  2014.  Evidence of Altered Age-Related Brain Cytoarchitecture in Mouse Models of Down syndrome: A Diffusional Kurtosis Imaging Study.  Magn Reson Imaging. [Epub ahead of print] Impact Factor: 2.022.

22.  Cunningham MA, Wirth JA, Freeman LR, Boger HA, Granholm AC, Gilkeson GS.  2014.  Estrogen Receptor Alpha Deficiency Protects Against Development Of Cognitive Impairment In Murine Lupus.  Journal of Neuroinflammation 11(1):171. Impact Factor: 4.90.

23. Farrand AQ, Gregory RA, Scofield MD, Helke KL, Boger HA.  2015.  Effects of aging on glutamate neurotransmission in the substantia nigra of Gdnf heterozygous mice.  Neurobiology of Aging  36(3):1569-76. Impact Factor: 4.853.

24.  Fortress AM, Hamlett ED, Vazey EM, Cass WA, Boger HA, Granholm AC. 2015.  Designer receptors enhance memory in a mouse model of Down syndrome.  J. Neurosci 35:1343-53.   Impact Factor:  6.747.

25. Turner TH, Granholm A-Ch, Duppstadt-Delambo A, Boger HA, Kumaraswamy G, Hinson V.  2015. Epidermal growth factor (EGF) is associated with memory and executive functioning in progressed Parkinson’s disease.  Journal of Alzheimer’s Disease and Parkinsonism 4:164. 

26. Scofield MD, Boger HA, Smith RJ, Haydon PG, Kalivas PW.  2015. Gq-DREADD Selectively Initiates Glial Glutamate Release and Inhibits Cue-induced Cocaine Seeking. Biol Psychiatry 78:441-51.  Impact Factor: 9.472.

27. Ledreux A, Boger HA, Hinson V, Cantwell K, Granholm AC.  2016. BDNF levels are increased by aminoindan and rasagiline in a double lesion model of Parkinson’s disease.  Brain Research 1631:34-45.  Impact Factor: 2.728.

28. Hamlett E, Boger HA, Ledreux A, Kelley CM, Mufson EJ, Falangola MF, Guilfoyle DN, Nixon RA, Patterson D, Duval N, Granholm AE. 2016.  Cognitive Impairment, Neuroimaging, and Alzheimer Neuropathology in Mouse Models of Down Syndrome.  Curr Alzheimer Res 13(1):35-52.

29.Spratt EG, Granholm AC, Carpenter L, Boger HA, Papa C, Logan S, Chaudhary H, Boatwright S-W, Brady KT.  2016.  Pilot Study and Review: Physiological Differences in BDNF, a Potential Biomarker in Males and Females with Autistic Disorder.  International Neuropsychiatric Disease Journal 3(1):19-26. Impact Factor: 2.154.

30. Scofield MD, Li H, Siemsen BH, Healey KL, Tran PK, Woronoff N, Boger HA, Kalivas PK, Reissner KJ. 2016. Cocaine self-administration and extinction leads to reduced glial fribrillary acidic protein expression and morphometric features of astrocytes in the nucleus accumbens core.  Biol Psychiatry 80(3):207-15.  Impact Factor:  9.472.

31. Rosenberger DS, Falangola MF, Ledreux A, Nie X, Suhre WM, Boger HA, Granholm AC. 2016. Memory and hippocampal architecture following short-term midazolam in western diet-treated rats.  Neurosci Lett 621:68-74.  Impact Factor: 2.026. 

32. Hascup KN, Lynn MK, Fitzgerald PJ, Kopchick JJ, Boger HA, Bartke A, Hascup ER.  2016. Enhanced Cognition and Hypoglutamatergic Signaling in a Growth Hormone Receptor Knockout Mouse Model of Successful Aging.  Journal of Gerontology: Biological Sciences (Epub ahead of print).  Impact Factor: 5.416.

33. Becker-Krail D, Farrand AQ, Boger HA, Lavin A.  2016. Effects of fingolimod administration in a genetic model of cognitive deficits.  J Neurosci Res 95:1174-1181.  Impact Factor: 2.974.

34. Farrand AQ, Gregory R, Helke KL, Boger HA.  2016. Altered glutamate neurotransmission in the dorsal striatum of MitoPark Mice.  Brain Research 1651:88-94.  Impact Factor:  2.728.

35. Hamlett ED, Goetzl EJ, Vasilevko V, Ledreux A, Boger HA, LaRosa A, Clark D, Carroll S, Iragui MC, Mufson EJ, Sabbagh M, Mohammed A, Hartley D, Fortea J, Doran E, Lott IT, Granholm A-Ch.  Neuronal exosome biomarkers reveal early Alzheimer pathology in Down syndrome.  2016.  J Alz and Dementia (Epub ahead of print). Impact Factor: 11.619.

36. Smith AC, Scofield MD, Heinsbroek JA, Gipson CD, Neuhofer D, Roberts-Wolfe DJ, Spencer S, Stankeviciute NM, Smith R, Allen NP, Lorang MR, Griffin WC, Boger HA, Kalivas PW.  2017.  Accumben nNOS interneurons regulate cocaine relapse. J Neurosci 37: 742-756.  Impact Factor: 5.9. 

37.  Farrand AQ, Gregory RA, Hinson VK, Helke KL, Boger HA.  2017.  Vagus nerve stimulation improves locomotion and neuronal function in a double lesion model of Parkinson’s disease.  Brain Stimulation 10(6):1045-1054. Impact Factor: 6.078.

38. Boger HA, Helke KL, Lynn MK, Revuelta G, Hinson V, Vaughan C.  Serum levels of alpha-synuclein and GDNF correlate with UPDRS scores of Parkinson’s disease patients and may be potential biomarkers for disease progression.  Movement Disorders (submitted). Impact Factor: 4.484.

39.  Scholpa NE, Lynn MK, Corum D, Boger HA*, Schnellmann RG*.  2017.  5-HT1F-Induced Mitochondrial Biogenesis for the Treatment of Parkinson’s Disease.  British Journal of Pharmacology 175(2):348-358. Impact Factor: 5.259.

40.  Hascup KN, Broderick SO, Russell MK, Boger HA, Hascup ER.  2019.  Diet-induced insulin resistance elevates hippocampal glutamate as well as VGLUT1 and GFAP expression in ABPP/PS1 Mice.  J Neurochem 148:219-237. Impact Factor:  4.870.

41.  Farrand AQ, Helke KL, Aponte-Cofresí L, Gooz MB, Gregory RA, Hinson VK, Boger HA.

2019.  Effects of vagus nerve stimulation are mediated in part by TrkB in a parkinson's disease model. Behav Brain Res. 373:1-13.  Impact Factor: 2.770

42.  Hamlett ED, Ledreux A, Gilmore A, Vazey EM, Aston-Jones G, Boger HA, Paredes D, Granholm AE.  2020.  Inhibitory designer receptors aggravate memory loss in a mouse model of down syndrome.  Neurobiol Dis. 134:1-12. Impact Factor:  5.160.

43.  Haque A, Samantaray S, Knaryan VH, Capone M, Hossain A, Matzelle D, Chandran R, Shields DC, Farrand AQ, Boger HA, Banik NL. 2020.  Calpain mediated expansion of CD4+ cytotoxic T cells in rodent models of Parkinson's disease.  Exp Neurol. 330:113315.  Impact Factor: 4.562.

44.  Farrand AQ, Verner R, McGuire R, Helke KL, Hinson VK, Boger HA.  2020.  Differential effects of vagus nerve stimulation paradigms guide clinical development for Parkinson's disease.  Brain Stim. 13(5):1323-1332 .  Impact Factor: 6.919.

45. Zhang Y, Song L, Dong H, Kim DS, Sun Z, Boger H, Wang Q, Wang H. 2020. Spinophilin-deficient mice are protected from diet-induced obesity and insulin resistance.  Am J Physiol Endocrinol Metab. 319(2):E354-E362.  Impact Factor:  3.469.

46.  Sims SK, Rizzo A, Howard K, Farrand A, Boger H, Adkins DL.  2020.  Comparative Enhancement of Motor Function and BDNF Expression Following Different Brain Stimulation Approaches in an Animal Model of Ischemic Stroke.   Neurorehabil Neural Repair. 10:1545968320952798. doi: 10.1177/1545968320952798. Online ahead of print.  Impact Factor:  4.711.

47.  Cheryl Dye, Kelsey Vinson, Lucy Ingram, Jo Pauling-Jones. 2021. Health Disparities: South Carolina Non-Hispanic Blacks Aged 50+ Report.  AARP South Carolina.

Chapters in Scholarly Books and Monographs:

1. Granholm A-Ch, Lockrow JP#, Boger HA, Buhusi M.  2010.  Locus Coeruleus and Norepinephrine.  The Encyclopedia of Movement Disorders.